Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole and Rifampicin on Olorofim PK in Healthy Subjects
NCT04171739Phase 1Completed
- Sponsor
- F2G
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive fungal infection (IFI), aspergillosis, scedosporiosis and 1 more (2 arms), sponsored by F2G. Primary endpoints: Maximum Plasma Concentration at 16 days and Area Under the Concentration-Time Curve to Last Quantifiable Concentration at 16 days. Started Nov 2019; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)aspergillosisscedosporiosislomentosporiosis
Beyond the preview
Go deeper on NCT04171739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171739.